Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(17 sites)
United States
University of Arkansas for Medical Sciences, Little Rock, Arkansas University of Southern California Keck Hospital, Los Angeles, California UC Irvine Medical Center, Orange, California Stanford University, Palo Alto, California University of California San Diego, San Diego, California University of California San Francisco, San Francisco, California University of Colorado Anschutz Medical Campus, Aurora, Colorado University of Chicago, Chicago, Illinois University of Iowa Health Care, Iowa City, Iowa SUNY Upstate Medical University, Syracuse, New York Atrium Health, Charlotte, North Carolina Duke University Hospital, Durham, North Carolina Wake Forest Baptist Medical Center, Winston-Salem, North Carolina Oregon Health and Science University, Portland, Oregon UTHealth Houston, Houston, Texas UVA Health University Medical Center, Charlottesville, Virginia Medical College of Wisconsin, Milwaukee, Wisconsin